Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.

Official Title

A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.* Males and females of childbearing potential must agree to utilize effective contraception methods.* Ability to understand and sign a written informed consent form.
Exclusion Criteria:
  1. * Females who are pregnant or breastfeeding.* Participation in any other clinical trial without prior approval from the Sponsor.* Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.* Subjects receiving ongoing therapy with contraindicated drugs.


Philip Grant
Philip Grant
Positive care doctor, Infectious disease doctor
Clinical Associate Professor, Medicine - Infectious Diseases
Andrew Zolopa

Contact us to find out if this trial is right for you.


Debbie Slamowitz
(650) 723-2804